Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.

Minnesota became the latest state to sue Insys Therapeutics Inc., accusing the drugmaker of illegally marketing a powerful fentanyl-based pain medicine, while a former employee pleaded guilty in New Jersey over bribing doctors to prescribe the drug.

Maryland’s attorney general filed a lawsuit seeking to enforce a subpoena the state sent Insys Therapeutics Inc. as part of a probe into allegations the drugmaker deceptively marketed a fentanyl-based cancer pain medicine.

Insys Therapeutics Inc. agreed to pay $4.45 million to resolve a lawsuit by Illinois’ attorney general claiming it deceptively marketed an addictive fentanyl-based cancer pain drug for off-label uses.